Developer docs
API playgroundTry for free, no card

Search company profiles

Accelerated Biosciences

Full company profile

uuid000bdbu

Namestring
Accelerated Biosciences
Legal namestring
Accelerated Biosciences, Inc.
Company typeenum
Private
Founded yearint
2014
Descriptiontext

Accelerated Biosciences is a regenerative medicine company that has built a proprietary platform around human trophoblast stem cells (hTSCs), which were originally isolated in 2003 by founder Jau-nan Lee from chorionic villi tissue obtained during a salpingectomy procedure. The company serves biopharmaceutical companies (from early-stage startups to established enterprises) and academic research institutions, supplying ethically sourced starting materials, iPSC products, exosomes, and genetically engineered platforms for therapeutic development, cell therapy, antibody production, and biomanufacturing applications. The company is incorporated in Delaware, headquartered in Philadelphia, PA, and operates cell-sourcing and exosome manufacturing in Taiwan.

The company's core offering is a platform-plus-products architecture anchored on the hTSC line, which is naturally immune privileged, genetically stable, and capable of 85x population doublings (theoretically producing up to 3.87x10^25 cells). The catalog includes hTSC RUO cell lines (ABX-001, ABX-002, ABX-003), hTSC-derived iPSCs (ABX-005, ABX-006) reprogrammed via an mRNA method without Yamanaka factors, hTSC-derived exosomes (ABX-004) produced in xeno-free 3D bioreactor systems, and two genetically engineered platforms — GEMS (up to 10 precision cutting sites for cell therapy, mAb, and viral vector applications) and CHO-GEMS (pre-engineered multi-specific antibody production). The platform is supported by 15 GMP-eligible cell lines and a patent portfolio of 54 granted patents and 46 pending applications across 12 families. Cells are sourced and processed under current Good Tissue Practice (cGTP) and conform to Global Ethical Standards and Clinical Cell Regulations.

The business model rests on three revenue streams: (1) sale of cell line products as Research Use Only (RUO) reagents with corresponding GMP-grade options available under commercial license, (2) licensing of hTSC technology and derived platforms to biopharma partners, and (3) GMP/CMC services delivered in collaboration with Theragent and Dark Horse Consulting. GTM is enterprise field sales driven by partnership inquiries through the company website, supplemented by attendance at industry conferences (ARM Meeting on the Mesa, BioJapan, Wilson Sonsini Biotech Summit, ISEV) and the company's own Trophoblast Stem Cell Forum series. In July 2025, the company formalized an exclusive US distributorship with Summit Pharmaceuticals International. The leadership team comprises CEO Yuta Lee, CFO Phillip King, CSO Sicco Popma (formerly Johnson & Johnson and UPenn), and COO Justin Hu, with Jau-nan Lee serving as Chairman.

Short descriptiontext

Accelerated Biosciences is a regenerative medicine company that develops a proprietary human trophoblast stem cell (hTSC) platform, supplying ethically sourced cell lines, iPSCs, exosomes, and genetically engineered platforms to biopharma companies and academic institutions for therapeutic development.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
1–10
akta.pro rankint
HeadquartersPhiladelphia, United States
HQ citystring
Philadelphia
HQ countrystring
United States
HQ regionstring
North America
Markets served

Serves global market

Offices1 record

Each record includes

City, Country, Type, Description, Source

Keyword5 values
regenerative medicine, stem cell research, cell line products, biopharmaceutical licensing, GMP cell manufacturing
Industry3 codes
PRIMARYHLAAAGAA
Stem Cell–Based Regenerative Therapies
Healthcare & Life Sciences/Biotechnology & Biologics/Regenerative Medicine & Tissue Engineering
SECONDARYHLAAABAE
Stem Cell Therapies (MSC/iPSC/HSC-derived)
Healthcare & Life Sciences/Biotechnology & Biologics/Cell Therapy (autologous/allogeneic)
SECONDARYHLAGAGAI
Raw Materials & Critical Reagents Supply (Media/Resins/Cytokines)
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Biopharma Manufacturing Services (Biologics/Cell & Gene)
NAICS code2 codes
  • Biological Product (except Diagnostic) Manufacturing325414
  • Research and Development in Biotechnology (except Nanobiotechnology)541714
SIC code1 code
  • Biological Products, (No Disgnostic Substances)2836
Product category
Regenerative Medicine
Social media profiles1 record
GTM motion1 record

Each record includes

Type, Description, Source

Revenue model3 records
1Cell Line Products
TypeOne Time License
Description

Sale of hTSC, iPSC, and exosome products as Research Use Only (RUO) reagents. Products include ABX-001 through ABX-006 with corresponding GMP options available under commercial license.

acceleratedbio.com
2Licensing and IP
TypeLicensing Royalties
Description

Licensing of hTSC technology and derived platforms to biopharma partners. Offers clear IP protection and global freedom-to-operate at attractive license terms.

acceleratedbio.com
3GMP/CMC Services
TypeProfessional Services
Description

De-risked starting material GMP and CMC issues for partners, with collaboration with Theragent and Dark Horse Consulting Group.

acceleratedbio.com
Marketing channels3 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels3 records

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components6 values
Technology or R&D, Personnel, Supply Chain, Operations, Marketing or Sales, Infrastructure
GTM typeB2B
B2B
Offering typeHardware or Manufacturing
Hardware or Manufacturing
Core offering1 text field

Accelerated Biosciences develops and supplies ethically sourced human trophoblast stem cell (hTSC) starting materials and derived genetically engineered platforms for regenerative medicine and biomanufacturing. Its product portfolio includes hTSC cell lines (ABX-001 to ABX-003), hTSC-derived iPSCs (ABX-005, ABX-006), hTSC-derived exosomes (ABX-004), and engineered platforms (GEMS and CHO-GEMS), sold as Research Use Only reagents with corresponding GMP-grade options available under commercial license to biopharma and academic partners.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 3 values shown
  • 85x population doublings capability
+2 more records
Product overview1 text field

Accelerated Biosciences offers a platform-plus-products architecture centered on its patented human trophoblast stem cell (hTSC) technology. The core hTSC Platform provides 15 GMP-eligible cell lines and corresponding RUO cell lines (ABX-001, ABX-002, ABX-003) as the foundational starting material for regenerative medicine. From this platform, the company derives iPSC products (ABX-005, ABX-006) using mRNA reprogramming without Yamanaka factors, and exosome products (ABX-004). The genetically engineered platforms include GEMS for precision genetic editing supporting cell therapy, mAB, and viral vector development, and CHO-GEMS for pre-engineered antibody production. All products are ethically sourced from chorionic villi tissue.

Product and service9 records
1ABX-001 hTSC 2003 RUO
CategoryStem cell line (RUO)
Description

Primary human trophoblast stem cells (hTSC) derived from chorionic villi (pre-placental tissue, female, Asian, approximately 6-8 weeks post-fertilization) with >70% viability post-thaw. Sold as Research Use Only with corresponding GMP cells available under commercial license to biopharma and academic researchers.

2ABX-002 hTSC 1810 RUO
CategoryStem cell line (RUO)
Description

Primary human trophoblast stem cells (hTSC) obtained and cultured under current Good Tissue Practice (cGTP) and conform to Global Ethical Standards and Clinical Cell Regulations. Guaranteed >70% viability post-thaw. Research Use Only with corresponding GMP cells available under commercial license.

3ABX-003 hTSC 1905 RUO
CategoryStem cell line (RUO)
Description

Primary human trophoblast stem cells (hTSC) obtained and cultured under cGTP. Female, Asian, approximately 6-8 weeks post-fertilization. Approximately 1 million cells per standard bank vial. Research Use Only with corresponding GMP cells available under commercial license.

4ABX-004 hTSC-derived Exosomes
CategoryExosome product
Description

Exosomes enriched from human trophoblast stem cells and xeno-free media. Produced by GMP hTSC expansion using a 3D bioreactor system. Available frozen at 1x10^10 particles/ml or lyophilized. Manufactured in Taiwan or USA. Research Use Only with commercial license available.

5ABX-005 hTSC 2003-derived iPSC Clone C1
CategoryiPSC product
Description

Induced Pluripotent Stem Cells (iPSC) derived from human trophoblast stem cells using mRNA method without Yamanaka factors. Manufactured by CDMO partner (Pluristyx) per standard operating procedures. 46, XX karyotype. Guaranteed >70% viability post-thaw. Research Use Only.

6ABX-006 hTSC 2003-derived iPSC Clone C6
CategoryiPSC product
Description

Induced Pluripotent Stem Cells (iPSC) derived from human trophoblast stem cells using mRNA method without Yamanaka factors. 46, XX karyotype, pluripotency markers OCT4, SSEA-4, NANOG, SOX2. Manufactured in USA by Pluristyx, Inc. Research Use Only with GMP cells under commercial license.

7GEMS (Genetically Engineered Modification System)
CategoryEngineered genetic editing platform
Description

Genetically engineered platform allowing precision complex genetic editing without random insertion for combination cell therapy, mAB, viral vector, and complex protein production. Features up to 10 engineered cutting sites, integrates with any cell line using any editing methods, and supports proof of concept for CAR, mAB, growth regulators, and safety switches.

8CHO-GEMS
CategoryAntibody production platform
Description

Pre-engineered antibody production platform designed for complex, multi-specific antibodies. Pre-designed cutting sites enable rapid prototyping of antibody designs. Pre-integrated with leading CDMOs for cost-effective transition from research to commercialization, with experienced cell-line development specialists supporting customers.

9hTSC Platform (licensing and IP package)
CategoryPlatform / technology license
Description

Patented human trophoblast stem cell (hTSC) platform offering core intellectual properties, protocols, and process designs. Includes 15 GMP-eligible cell lines and corresponding RUO cell lines, with global freedom-to-operate at attractive license terms. Naturally immune privileged and genetically stable with exceptional expansion capacity.

Scale indicator4 records

Each record includes

Type, Value, Description, Source

Partnership9 partners
1Summit Pharmaceuticals International
Strategic tierCoreTypeChannel Partner/ Reseller/ DistributorAnnounced on2025-07-15
Description

Signed an exclusive distributorship agreement with Summit Pharmaceuticals International, a US cell provider, expanding distribution reach in the US market.

acceleratedbio.com
Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2024-12-16
Description

Accelerated Biosciences and Stemmatters collaborated to offer iPSC derived from human trophoblast stem cells. This partnership combines Accelerated Bio's hTSC platform with Stemmatters' expertise in iPSC differentiation.

Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2024-07-11
Description

Accelerated Bio and Pluristyx created Clinical Grade Induced Pluripotent Stem Cells from reprogramming human trophoblast stem cells. Pluristyx serves as the CDMO manufacturer for iPSC products (ABX-005, ABX-006).

Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2024-07-10
Description

Revolutionizing Cancer Treatment: Wistar and Accelerated Biosciences collaborate to pioneer transformative immune cell therapies leveraging the hTSC platform.

Strategic tierCoreTypeOEM/ Whitelabel/ Licensing PartnerAnnounced on2024-06-05
Description

License of human trophoblast stem cells (hTSC) to Agathos Biologics for development of ethically sourced research and biomanufacturing platforms.

Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2024-05-16
Description

Accelerated Biosciences and Spanios partner to advance therapeutic design across solid tumor cancers, leveraging hTSC-derived platforms.

Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2024-05-02
Description

Mekonos entered partnership agreement with Accelerated Biosciences to develop and commercialize engineered human trophoblast stem cells (hTSCs) for biomanufacturing applications.

Strategic tierCoreTypeImplementation/ SI/ Consulting Partner
Description

Theragent oversees GMP and CMC processes for Accelerated Biosciences, ensuring consistent product quality and manufacturing standards.

Strategic tierCoreTypeImplementation/ SI/ Consulting Partner
Description

Dark Horse Consulting Group provides assurance as to manufacturing capabilities and suitability of source material for Accelerated Biosciences.

Recent move6 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight6 records

Each record includes

Type, Description

Peers10 records
TypeDirect peer
Description

FUJIFILM Cellular Dynamics is a leading commercial supplier of iPSC-derived cells and tissues used for drug discovery, cell therapy, and regenerative medicine research. Directly comparable as a starting-material/cell-line platform vendor to biopharma and academia.

TypeDirect peer
Description

STEMCELL Technologies is a major developer and supplier of cell culture media, reagents, and cell isolation products supporting stem cell research and cell therapy development. Comparable as a stem cell research tools and reagents provider serving biopharma and academic customers.

TypeBroad incumbent
Description

Lonza is a global CDMO and cell therapy manufacturing platform serving cell and gene therapy developers worldwide. Comparable as a broad incumbent providing GMP manufacturing services and cell therapy starting materials to biopharma.

TypeBroad incumbent
Description

Thermo Fisher's Gibco business is a dominant supplier of cell culture media, reagents, and primary cells used in regenerative medicine and cell therapy. Comparable as a broad incumbent life sciences tools vendor serving overlapping biopharma customers.

TypeDirect peer
Description

Pluristyx is an iPSC-focused CDMO and iPSC line developer that manufactures clinical-grade iPSCs, including ABX's hTSC-derived iPSC products. Comparable as an iPSC platform/CDMO serving regenerative medicine developers.

6Cynata Therapeutics
TypeEmerging player
Description

Cynata is a clinical-stage company developing iPSC-derived MSC therapies for inflammatory and immune-mediated diseases. Comparable as a regenerative medicine player leveraging iPSC/pluripotent starting materials to develop cell therapies.

TypeEmerging player
Description

Fate Therapeutics is a clinical-stage iPSC-derived cell therapy company developing off-the-shelf NK and T-cell cancer immunotherapies. Comparable as a regenerative medicine player using iPSC/pluripotent platforms for cell therapy development.

TypeEmerging player
Description

Century Therapeutics is a clinical-stage company developing iPSC-derived allogeneic cell therapies for cancer and autoimmune diseases. Comparable as a regenerative medicine player using iPSC starting materials for off-the-shelf cell therapies.

TypeEmerging player
Description

Mesoblast is a commercial-stage regenerative medicine company developing mesenchymal lineage cell therapies for inflammatory and cardiovascular diseases. Comparable as a stem cell-based therapeutic developer targeting similar regenerative medicine indications.

TypeBroad incumbent
Description

Cytiva supplies bioprocessing technologies, single-use systems, and cell therapy manufacturing solutions to the regenerative medicine industry. Comparable as a broad incumbent providing tools and infrastructure for cell therapy and biomanufacturing customers.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat6 records

Each record includes

Type, Details

Key risks6 records

Each record includes

Headline, Details, Source

Key highlights7 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Segment2 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile2 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Feature5 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles4 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
Compliance2 records

Each record includes

Name, Class, Description

Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Accelerated Biosciences

Regenerative Medicineacceleratedbio.com

Accelerated Biosciences is a regenerative medicine company that develops a proprietary human trophoblast stem cell (hTSC) platform, supplying ethically sourced cell lines, iPSCs, exosomes, and genetically engineered platforms to biopharma companies and academic institutions for therapeutic development.

What Accelerated Biosciences does

Accelerated Biosciences is a regenerative medicine company that has built a proprietary platform around human trophoblast stem cells (hTSCs), which were originally isolated in 2003 by founder Jau-nan Lee from chorionic villi tissue obtained during a salpingectomy procedure. The company serves biopharmaceutical companies (from early-stage startups to established enterprises) and academic research institutions, supplying ethically sourced starting materials, iPSC products, exosomes, and genetically engineered platforms for therapeutic development, cell therapy, antibody production, and biomanufacturing applications. The company is incorporated in Delaware, headquartered in Philadelphia, PA, and operates cell-sourcing and exosome manufacturing in Taiwan.

The company's core offering is a platform-plus-products architecture anchored on the hTSC line, which is naturally immune privileged, genetically stable, and capable of 85x population doublings (theoretically producing up to 3.87x10^25 cells). The catalog includes hTSC RUO cell lines (ABX-001, ABX-002, ABX-003), hTSC-derived iPSCs (ABX-005, ABX-006) reprogrammed via an mRNA method without Yamanaka factors, hTSC-derived exosomes (ABX-004) produced in xeno-free 3D bioreactor systems, and two genetically engineered platforms — GEMS (up to 10 precision cutting sites for cell therapy, mAb, and viral vector applications) and CHO-GEMS (pre-engineered multi-specific antibody production). The platform is supported by 15 GMP-eligible cell lines and a patent portfolio of 54 granted patents and 46 pending applications across 12 families. Cells are sourced and processed under current Good Tissue Practice (cGTP) and conform to Global Ethical Standards and Clinical Cell Regulations.

The business model rests on three revenue streams: (1) sale of cell line products as Research Use Only (RUO) reagents with corresponding GMP-grade options available under commercial license, (2) licensing of hTSC technology and derived platforms to biopharma partners, and (3) GMP/CMC services delivered in collaboration with Theragent and Dark Horse Consulting. GTM is enterprise field sales driven by partnership inquiries through the company website, supplemented by attendance at industry conferences (ARM Meeting on the Mesa, BioJapan, Wilson Sonsini Biotech Summit, ISEV) and the company's own Trophoblast Stem Cell Forum series. In July 2025, the company formalized an exclusive US distributorship with Summit Pharmaceuticals International. The leadership team comprises CEO Yuta Lee, CFO Phillip King, CSO Sicco Popma (formerly Johnson & Johnson and UPenn), and COO Justin Hu, with Jau-nan Lee serving as Chairman.

Accelerated Biosciences firmographics

Firmographics
Name
Accelerated Biosciences
Legal name
Accelerated Biosciences, Inc.
Website
https://acceleratedbio.com
Company type
Private
Founded year
2014
Operating status
Operating
Headcount range
1–10 employees
Short description
Accelerated Biosciences is a regenerative medicine company that develops a proprietary human trophoblast stem cell (hTSC) platform, supplying ethically sourced cell lines, iPSCs, exosomes, and genetically engineered platforms to biopharma companies and academic institutions for therapeutic development.
Ownership category
akta.pro rank

Accelerated Biosciences industry classification

Industry
Product category
Regenerative Medicine
NAICS
Biological Product (except Diagnostic) Manufacturing (325414), Research and Development in Biotechnology (except Nanobiotechnology) (541714)
SIC
Biological Products, (No Disgnostic Substances) (2836)
akta.pro industry
PRIMARYHLAAAGAA
Stem Cell–Based Regenerative Therapies
Healthcare & Life Sciences/Biotechnology & Biologics/Regenerative Medicine & Tissue Engineering
SECONDARYHLAAABAE
Stem Cell Therapies (MSC/iPSC/HSC-derived)
Healthcare & Life Sciences/Biotechnology & Biologics/Cell Therapy (autologous/allogeneic)
SECONDARYHLAGAGAI
Raw Materials & Critical Reagents Supply (Media/Resins/Cytokines)
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Biopharma Manufacturing Services (Biologics/Cell & Gene)

Keywords

  • Regenerative medicine
  • Stem cell research
  • Cell line products
  • Biopharmaceutical licensing
  • GMP cell manufacturing

Where Accelerated Biosciences is headquartered

Location

Headquarters

HQ city
Philadelphia
HQ country
United States
HQ region
North America

Offices1 record

Markets served

Accelerated Biosciences business model

Business model
GTM type
B2B
Offering type
Hardware or Manufacturing
Cost components
Technology or R&D, Personnel, Supply Chain, Operations, Marketing or Sales, Infrastructure

Revenue model

  1. Cell Line Products: Sale of hTSC, iPSC, and exosome products as Research Use Only (RUO) reagents. Products include ABX-001 through ABX-006 with corresponding GMP options available under commercial license.
  2. Licensing and IP: Licensing of hTSC technology and derived platforms to biopharma partners. Offers clear IP protection and global freedom-to-operate at attractive license terms.
  3. GMP/CMC Services: De-risked starting material GMP and CMC issues for partners, with collaboration with Theragent and Dark Horse Consulting Group.

Go-to-market motion1 record

Distribution channels3 records

Marketing channels3 records

Accelerated Biosciences product offering

Product offering

Core offering

Accelerated Biosciences develops and supplies ethically sourced human trophoblast stem cell (hTSC) starting materials and derived genetically engineered platforms for regenerative medicine and biomanufacturing. Its product portfolio includes hTSC cell lines (ABX-001 to ABX-003), hTSC-derived iPSCs (ABX-005, ABX-006), hTSC-derived exosomes (ABX-004), and engineered platforms (GEMS and CHO-GEMS), sold as Research Use Only reagents with corresponding GMP-grade options available under commercial license to biopharma and academic partners.

Product overview

Accelerated Biosciences offers a platform-plus-products architecture centered on its patented human trophoblast stem cell (hTSC) technology. The core hTSC Platform provides 15 GMP-eligible cell lines and corresponding RUO cell lines (ABX-001, ABX-002, ABX-003) as the foundational starting material for regenerative medicine. From this platform, the company derives iPSC products (ABX-005, ABX-006) using mRNA reprogramming without Yamanaka factors, and exosome products (ABX-004). The genetically engineered platforms include GEMS for precision genetic editing supporting cell therapy, mAB, and viral vector development, and CHO-GEMS for pre-engineered antibody production. All products are ethically sourced from chorionic villi tissue.

Differentiator

Problem solved

Functional benefit

Products and services

  • ABX-001 hTSC 2003 RUO Primary human trophoblast stem cells (hTSC) derived from chorionic villi (pre-placental tissue, female, Asian, approximately 6-8 weeks post-fertilization) with >70% viability post-thaw. Sold as Research Use Only with corresponding GMP cells available under commercial license to biopharma and academic researchers.
  • ABX-002 hTSC 1810 RUO Primary human trophoblast stem cells (hTSC) obtained and cultured under current Good Tissue Practice (cGTP) and conform to Global Ethical Standards and Clinical Cell Regulations. Guaranteed >70% viability post-thaw. Research Use Only with corresponding GMP cells available under commercial license.
  • ABX-003 hTSC 1905 RUO Primary human trophoblast stem cells (hTSC) obtained and cultured under cGTP. Female, Asian, approximately 6-8 weeks post-fertilization. Approximately 1 million cells per standard bank vial. Research Use Only with corresponding GMP cells available under commercial license.
  • ABX-004 hTSC-derived Exosomes Exosomes enriched from human trophoblast stem cells and xeno-free media. Produced by GMP hTSC expansion using a 3D bioreactor system. Available frozen at 1x10^10 particles/ml or lyophilized. Manufactured in Taiwan or USA. Research Use Only with commercial license available.
  • ABX-005 hTSC 2003-derived iPSC Clone C1 Induced Pluripotent Stem Cells (iPSC) derived from human trophoblast stem cells using mRNA method without Yamanaka factors. Manufactured by CDMO partner (Pluristyx) per standard operating procedures. 46, XX karyotype. Guaranteed >70% viability post-thaw. Research Use Only.
  • ABX-006 hTSC 2003-derived iPSC Clone C6 Induced Pluripotent Stem Cells (iPSC) derived from human trophoblast stem cells using mRNA method without Yamanaka factors. 46, XX karyotype, pluripotency markers OCT4, SSEA-4, NANOG, SOX2. Manufactured in USA by Pluristyx, Inc. Research Use Only with GMP cells under commercial license.
  • GEMS (Genetically Engineered Modification System) Genetically engineered platform allowing precision complex genetic editing without random insertion for combination cell therapy, mAB, viral vector, and complex protein production. Features up to 10 engineered cutting sites, integrates with any cell line using any editing methods, and supports proof of concept for CAR, mAB, growth regulators, and safety switches.
  • CHO-GEMS Pre-engineered antibody production platform designed for complex, multi-specific antibodies. Pre-designed cutting sites enable rapid prototyping of antibody designs. Pre-integrated with leading CDMOs for cost-effective transition from research to commercialization, with experienced cell-line development specialists supporting customers.
  • hTSC Platform (licensing and IP package) Patented human trophoblast stem cell (hTSC) platform offering core intellectual properties, protocols, and process designs. Includes 15 GMP-eligible cell lines and corresponding RUO cell lines, with global freedom-to-operate at attractive license terms. Naturally immune privileged and genetically stable with exceptional expansion capacity.

Quantifiable outcome

  • 85x population doublings capability
  • +2 more outcomes

Companies that use Accelerated Biosciences

Customer profile

Segments2 records

Ideal customer profiles2 records

Accelerated Biosciences technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Feature5 records

Accelerated Biosciences partnerships and signals

Strategic signal

Partnerships

Nine partnerships are on record, tiered core.

  • Summit Pharmaceuticals InternationalcoreChannel Partner/ Reseller/ Distributor · 15 July 2025Signed an exclusive distributorship agreement with Summit Pharmaceuticals International, a US cell provider, expanding distribution reach in the US market.
  • StemmatterscoreStrategic or Co-development Partner · 16 December 2024Accelerated Biosciences and Stemmatters collaborated to offer iPSC derived from human trophoblast stem cells. This partnership combines Accelerated Bio's hTSC platform with Stemmatters' expertise in iPSC differentiation.
  • PluristyxcoreStrategic or Co-development Partner · 11 July 2024Accelerated Bio and Pluristyx created Clinical Grade Induced Pluripotent Stem Cells from reprogramming human trophoblast stem cells. Pluristyx serves as the CDMO manufacturer for iPSC products (ABX-005, ABX-006).
  • Wistar InstitutecoreStrategic or Co-development Partner · 10 July 2024Revolutionizing Cancer Treatment: Wistar and Accelerated Biosciences collaborate to pioneer transformative immune cell therapies leveraging the hTSC platform.
  • Agathos BiologicscoreOEM/ Whitelabel/ Licensing Partner · 5 June 2024License of human trophoblast stem cells (hTSC) to Agathos Biologics for development of ethically sourced research and biomanufacturing platforms.
  • SpanioscoreStrategic or Co-development Partner · 16 May 2024Accelerated Biosciences and Spanios partner to advance therapeutic design across solid tumor cancers, leveraging hTSC-derived platforms.
  • MekonoscoreStrategic or Co-development Partner · 2 May 2024Mekonos entered partnership agreement with Accelerated Biosciences to develop and commercialize engineered human trophoblast stem cells (hTSCs) for biomanufacturing applications.
  • TheragentcoreImplementation/ SI/ Consulting PartnerTheragent oversees GMP and CMC processes for Accelerated Biosciences, ensuring consistent product quality and manufacturing standards.
  • Dark Horse Consulting GroupcoreImplementation/ SI/ Consulting PartnerDark Horse Consulting Group provides assurance as to manufacturing capabilities and suitability of source material for Accelerated Biosciences.

Scale indicators4 records

Recent moves6 records

Expansion highlights6 records

Accelerated Biosciences competitors and assessment

Company assessment

Direct peers

  • FUJIFILM Cellular Dynamics: FUJIFILM Cellular Dynamics is a leading commercial supplier of iPSC-derived cells and tissues used for drug discovery, cell therapy, and regenerative medicine research. Directly comparable as a starting-material/cell-line platform vendor to biopharma and academia.
  • STEMCELL Technologies: STEMCELL Technologies is a major developer and supplier of cell culture media, reagents, and cell isolation products supporting stem cell research and cell therapy development. Comparable as a stem cell research tools and reagents provider serving biopharma and academic customers.
  • Pluristyx: Pluristyx is an iPSC-focused CDMO and iPSC line developer that manufactures clinical-grade iPSCs, including ABX's hTSC-derived iPSC products. Comparable as an iPSC platform/CDMO serving regenerative medicine developers.

Broad incumbents

  • Lonza Cell & Gene Technologies: Lonza is a global CDMO and cell therapy manufacturing platform serving cell and gene therapy developers worldwide. Comparable as a broad incumbent providing GMP manufacturing services and cell therapy starting materials to biopharma.
  • Thermo Fisher Scientific (Gibco Cell Culture): Thermo Fisher's Gibco business is a dominant supplier of cell culture media, reagents, and primary cells used in regenerative medicine and cell therapy. Comparable as a broad incumbent life sciences tools vendor serving overlapping biopharma customers.
  • Cytiva (Danaher): Cytiva supplies bioprocessing technologies, single-use systems, and cell therapy manufacturing solutions to the regenerative medicine industry. Comparable as a broad incumbent providing tools and infrastructure for cell therapy and biomanufacturing customers.

Emerging players

  • Cynata Therapeutics: Cynata is a clinical-stage company developing iPSC-derived MSC therapies for inflammatory and immune-mediated diseases. Comparable as a regenerative medicine player leveraging iPSC/pluripotent starting materials to develop cell therapies.
  • Fate Therapeutics: Fate Therapeutics is a clinical-stage iPSC-derived cell therapy company developing off-the-shelf NK and T-cell cancer immunotherapies. Comparable as a regenerative medicine player using iPSC/pluripotent platforms for cell therapy development.
  • Century Therapeutics: Century Therapeutics is a clinical-stage company developing iPSC-derived allogeneic cell therapies for cancer and autoimmune diseases. Comparable as a regenerative medicine player using iPSC starting materials for off-the-shelf cell therapies.
  • Mesoblast: Mesoblast is a commercial-stage regenerative medicine company developing mesenchymal lineage cell therapies for inflammatory and cardiovascular diseases. Comparable as a stem cell-based therapeutic developer targeting similar regenerative medicine indications.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat6 records

Key risks6 records

Key highlights7 records

Customer concentration

Accelerated Biosciences social profiles

Digital presence

Accelerated Biosciences compliance and trust

Trust signal

Compliance2 records

Accelerated Biosciences financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Accelerated Biosciences leadership team

Management profile

Number of profiles

Profiles4 records

Accelerated Biosciences funding detail

Funding detail

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Accelerated Biosciences M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Accelerated Biosciences

What does Accelerated Biosciences do?

Accelerated Biosciences develops and supplies ethically sourced human trophoblast stem cell (hTSC) starting materials and derived genetically engineered platforms for regenerative medicine and biomanufacturing. Its product portfolio includes hTSC cell lines (ABX-001 to ABX-003), hTSC-derived iPSCs (ABX-005, ABX-006), hTSC-derived exosomes (ABX-004), and engineered platforms (GEMS and CHO-GEMS), sold as Research Use Only reagents with corresponding GMP-grade options available under commercial license to biopharma and academic partners.

Is Accelerated Biosciences a public or private company?

Accelerated Biosciences is a private company. It is classified as founder individual operated bootstrapped and is currently operating.

When was Accelerated Biosciences founded?

Accelerated Biosciences was founded in 2014. It employs 1 to 10 people.

Where is Accelerated Biosciences based?

Accelerated Biosciences is headquartered in Philadelphia, United States, in the North America region.

How does Accelerated Biosciences make money?

Three revenue lines are on record. Cell Line Products are the primary driver. The others are licensing and IP and GMP/CMC Services.

Who are Accelerated Biosciences's main competitors?

Direct peers on record are FUJIFILM Cellular Dynamics, STEMCELL Technologies and Pluristyx. Broad incumbents are Lonza Cell & Gene Technologies, Thermo Fisher Scientific (Gibco Cell Culture) and Cytiva (Danaher). Emerging players are Cynata Therapeutics, Fate Therapeutics, Century Therapeutics and Mesoblast.

Does Accelerated Biosciences have an API?

No public API is recorded for Accelerated Biosciences.

What industry is Accelerated Biosciences in?

Accelerated Biosciences's product category is Regenerative Medicine. Its primary akta.pro industry code is HLAAAGAA, Stem Cell–Based Regenerative Therapies, with a secondary code of HLAAABAE, Stem Cell Therapies (MSC/iPSC/HSC-derived). Its NAICS code is 325414 and its SIC code is 2836.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
PR NewswireAccelerated Biosciences and Spanios Partner to Advance Therapeutic Design Across Solid Tumor CancersSpanios and Accelerated Biosciences announced a partnership to combine Spanios' proprietary 3D tumoroid platforms with Accelerated Bio's human trophoblast stem cell (hTSC) platform to advance therapeutic design across solid tumor cancers. The collaboration will leverage hTSC-derived effector cells, which have demonstrated NK-like behaviors against cancer cells, particularly for ovarian, colorectal, and other challenging solid tumors. The companies aim to generate clinically relevant data and demonstrate the versatility of the hTSC platform for next-generation precision medicine therapies.PR NewswireTheragent Secures Novel Stem Cell Bank Production Contract with Accelerated BiosciencesTheragent, a cell therapy contract development and manufacturing organization (CDMO) based in Arcadia, California, has entered into an agreement with Accelerated Biosciences to produce a cGMP-grade master cell bank (MCB) for Accelerated Biosciences' novel human Trophoblast Stem Cells (hTSCs). The hTSCs are pluripotent, immune-privileged stem cells derived from an ethical source with patent protection, designed to serve as starting material for next-generation cell and gene therapies. The master cell bank, accompanied by a regulatory support package, will be available for purchase or licensing to industry partners in Q1 2023.BioSpaceAccelerated Biosciences and Pluristyx Announce Availability of Human Trophoblast Stem Cell (hTSC) Derived iPSCsAccelerated Biosciences and Pluristyx announced an agreement for Pluristyx to provide iPSCs derived from hTSCs under Good Tissue Practices for research evaluation. The iPSCs are available in a Ready-to-Differentiate format and can transition to clinical-grade versions. Clinical-grade hTSC-iPSCs will be available in 2023 with a complete regulatory support package.